Skip to main content
. 2019 Sep 30;26(1):45–53. doi: 10.3350/cmh.2019.0031

Figure 5.

Figure 5.

Vimentin expression in HepG2 (R) cells in response to: withaferin A (WA) and a combination of sorafenib (S; 5 μM) and WA. HepG2 (R), HepG2 sorafenib-resistant. *P=0.034.